• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多靶标计算机预测丝裂原活化蛋白激酶相互作用激酶抑制剂

Multi-Target In Silico Prediction of Inhibitors for Mitogen-Activated Protein Kinase-Interacting Kinases.

机构信息

LAQV-REQUIMTE/Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal.

Dr. B. C. Roy College of Pharmacy and Allied Health Sciences, Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur 713212, India.

出版信息

Biomolecules. 2021 Nov 10;11(11):1670. doi: 10.3390/biom11111670.

DOI:10.3390/biom11111670
PMID:34827668
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8615736/
Abstract

The inhibitors of two isoforms of mitogen-activated protein kinase-interacting kinases (i.e., MNK-1 and MNK-2) are implicated in the treatment of a number of diseases including cancer. This work reports, for the first time, a multi-target (or multi-tasking) in silico modeling approach (mt-QSAR) for probing the inhibitory potential of these isoforms against MNKs. Linear and non-linear mt-QSAR classification models were set up from a large dataset of 1892 chemicals tested under a variety of assay conditions, based on the Box-Jenkins moving average approach, along with a range of feature selection algorithms and machine learning tools, out of which the most predictive one (>90% overall accuracy) was used for mechanistic interpretation of the likely inhibition of MNK-1 and MNK-2. Considering that the latter model is suitable for virtual screening of chemical libraries-i.e., commercial, non-commercial and in-house sets, it was made publicly accessible as a ready-to-use FLASK-based application. Additionally, this work employed a focused kinase library for virtual screening using an mt-QSAR model. The virtual hits identified in this process were further filtered by using a similarity search, in silico prediction of drug-likeness, and ADME profiles as well as synthetic accessibility tools. Finally, molecular dynamic simulations were carried out to identify and select the most promising virtual hits. The information gathered from this work can supply important guidelines for the discovery of novel MNK-1/2 inhibitors as potential therapeutic agents.

摘要

两种丝裂原活化蛋白激酶相互作用激酶(即 MNK-1 和 MNK-2)抑制剂被认为可用于治疗多种疾病,包括癌症。本研究首次报道了一种多靶标(或多任务)的计算建模方法(mt-QSAR),用于探测这些同工酶对 MNKs 的抑制潜力。根据 Box-Jenkins 移动平均方法,结合一系列特征选择算法和机器学习工具,从在各种测定条件下测试的 1892 种化学物质的大型数据集构建线性和非线性 mt-QSAR 分类模型,其中最具预测性的模型(>90%的整体准确性)用于对 MNK-1 和 MNK-2 的可能抑制作用进行机制解释。考虑到该后一种模型适用于化学文库的虚拟筛选,即商业、非商业和内部文库,我们将其构建为一个基于 Flask 的可公开访问的即用型应用程序。此外,本研究还使用 mt-QSAR 模型对聚焦激酶文库进行了虚拟筛选。在这个过程中确定的虚拟命中物进一步通过相似性搜索、药物相似性的计算预测、ADME 特征以及合成可及性工具进行筛选。最后,进行分子动力学模拟以识别和选择最有前途的虚拟命中物。本工作中收集的信息可为发现新型 MNK-1/2 抑制剂作为潜在治疗剂提供重要指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d4c/8615736/2c943cc6d248/biomolecules-11-01670-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d4c/8615736/35275f90edb4/biomolecules-11-01670-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d4c/8615736/088a27ab6ee4/biomolecules-11-01670-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d4c/8615736/b229b103f4a1/biomolecules-11-01670-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d4c/8615736/4f2c54278e14/biomolecules-11-01670-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d4c/8615736/2c943cc6d248/biomolecules-11-01670-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d4c/8615736/35275f90edb4/biomolecules-11-01670-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d4c/8615736/088a27ab6ee4/biomolecules-11-01670-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d4c/8615736/b229b103f4a1/biomolecules-11-01670-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d4c/8615736/4f2c54278e14/biomolecules-11-01670-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d4c/8615736/2c943cc6d248/biomolecules-11-01670-g005.jpg

相似文献

1
Multi-Target In Silico Prediction of Inhibitors for Mitogen-Activated Protein Kinase-Interacting Kinases.多靶标计算机预测丝裂原活化蛋白激酶相互作用激酶抑制剂
Biomolecules. 2021 Nov 10;11(11):1670. doi: 10.3390/biom11111670.
2
AKT Inhibitors: The Road Ahead to Computational Modeling-Guided Discovery.AKT 抑制剂:通往计算建模指导发现的道路。
Int J Mol Sci. 2021 Apr 11;22(8):3944. doi: 10.3390/ijms22083944.
3
Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening.基于突变的诱导契合虚拟高通量筛选发现新型 Mnk 抑制剂。
Chem Biol Drug Des. 2019 Oct;94(4):1813-1823. doi: 10.1111/cbdd.13585. Epub 2019 Aug 4.
4
Multi-Target In-Silico modeling strategies to discover novel angiotensin converting enzyme and neprilysin dual inhibitors.多靶点计算机模拟策略发现新型血管紧张素转换酶和 Neprilysin 双重抑制剂。
Sci Rep. 2024 Jul 10;14(1):15991. doi: 10.1038/s41598-024-66230-7.
5
Probing the binding mechanism of Mnk inhibitors by docking and molecular dynamics simulations.通过对接和分子动力学模拟探究Mnk抑制剂的结合机制。
Biochemistry. 2015 Jan 13;54(1):32-46. doi: 10.1021/bi501261j. Epub 2014 Dec 5.
6
An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.一种用于发现高效且选择性 Mnk 抑制剂的综合方法:筛选、合成和 SAR 分析。
Eur J Med Chem. 2015 Oct 20;103:539-50. doi: 10.1016/j.ejmech.2015.09.008. Epub 2015 Sep 9.
7
Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.丝裂原活化蛋白激酶(MAPK)相互作用激酶1和2(MNK1和MNK2)作为癌症治疗靶点:MNK抑制剂开发的最新进展
Curr Med Chem. 2017;24(28):3025-3053. doi: 10.2174/0929867324666170203123427.
8
Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.5-(2-(苯胺基)嘧啶-4-基)噻唑-2(3H)-酮衍生物作为强效Mnk2抑制剂的发现:合成、构效关系分析及生物学评价
ChemMedChem. 2014 May;9(5):962-72. doi: 10.1002/cmdc.201300552. Epub 2014 Feb 12.
9
Multi-Target Chemometric Modelling, Fragment Analysis and Virtual Screening with ERK Inhibitors as Potential Anticancer Agents.多靶点化学计量学建模、片段分析和虚拟筛选,以 ERK 抑制剂作为潜在的抗癌药物。
Molecules. 2019 Oct 30;24(21):3909. doi: 10.3390/molecules24213909.
10
Design, Synthesis and Bioactivity Evaluation of 4,6-Disubstituted Pyrido[3,2-]pyrimidine Derivatives as Mnk and HDAC Inhibitors.设计、合成及 4,6-取代吡啶并[3,2-d]嘧啶衍生物作为 Mnk 和 HDAC 抑制剂的生物活性评价。
Molecules. 2020 Sep 21;25(18):4318. doi: 10.3390/molecules25184318.

引用本文的文献

1
Shaping the Future of Obesity Treatment: In Silico Multi-Modeling of IP6K1 Inhibitors for Obesity and Metabolic Dysfunction.塑造肥胖治疗的未来:IP6K1抑制剂治疗肥胖和代谢功能障碍的计算机多模型研究
Pharmaceuticals (Basel). 2024 Feb 19;17(2):263. doi: 10.3390/ph17020263.
2
In Silico Modeling and Structural Analysis of Soluble Epoxide Hydrolase Inhibitors for Enhanced Therapeutic Design.计算机模拟与可溶性环氧化物水解酶抑制剂的结构分析及其在增强治疗设计中的应用。
Molecules. 2023 Aug 31;28(17):6379. doi: 10.3390/molecules28176379.
3
MNK Proteins as Therapeutic Targets in Leukemia.

本文引用的文献

1
Charged aerosol detector response modeling for fatty acids based on experimental settings and molecular features: a machine learning approach.基于实验设置和分子特征的脂肪酸带电气溶胶探测器响应建模:一种机器学习方法
J Cheminform. 2021 Jul 15;13(1):53. doi: 10.1186/s13321-021-00532-0.
2
Progress in developing MNK inhibitors.MNK 抑制剂的研究进展。
Eur J Med Chem. 2021 Jul 5;219:113420. doi: 10.1016/j.ejmech.2021.113420. Epub 2021 Apr 2.
3
QSAR-Co-X: an open source toolkit for multitarget QSAR modelling.QSAR-Co-X:用于多靶点定量构效关系建模的开源工具包。
MNK蛋白作为白血病的治疗靶点
Onco Targets Ther. 2023 Apr 21;16:283-295. doi: 10.2147/OTT.S370874. eCollection 2023.
4
Support Vector Machine-Based Global Classification Model of the Toxicity of Organic Compounds to .基于支持向量机的有机化合物对 毒性的全局分类模型。
Molecules. 2023 Mar 16;28(6):2703. doi: 10.3390/molecules28062703.
5
characterization of aryl benzoyl hydrazide derivatives as potential inhibitors of RdRp enzyme of H5N1 influenza virus.芳基苯甲酰肼衍生物作为H5N1流感病毒RdRp酶潜在抑制剂的表征
Front Pharmacol. 2022 Sep 26;13:1004255. doi: 10.3389/fphar.2022.1004255. eCollection 2022.
6
Do AutoML-Based QSAR Models Fulfill OECD Principles for Regulatory Assessment? A 5-HT Receptor Case.基于自动机器学习的定量构效关系模型是否符合经合组织监管评估原则?以5-羟色胺受体为例。
Pharmaceutics. 2022 Jul 6;14(7):1415. doi: 10.3390/pharmaceutics14071415.
7
Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy.用于癌症治疗的多靶点酪氨酸激酶抑制剂纳米颗粒递送系统。
Mater Today Bio. 2022 Jul 12;16:100358. doi: 10.1016/j.mtbio.2022.100358. eCollection 2022 Dec.
8
Moving Average-Based Multitasking In Silico Classification Modeling: Where Do We Stand and What Is Next?基于移动平均的计算机辅助分类模型的多任务处理:现状如何,下一步如何发展?
Int J Mol Sci. 2022 Apr 29;23(9):4937. doi: 10.3390/ijms23094937.
9
PTML Modeling for Pancreatic Cancer Research: In Silico Design of Simultaneous Multi-Protein and Multi-Cell Inhibitors.用于胰腺癌研究的PTML建模:同时针对多种蛋白质和多种细胞的抑制剂的计算机模拟设计
Biomedicines. 2022 Feb 18;10(2):491. doi: 10.3390/biomedicines10020491.
J Cheminform. 2021 Apr 15;13(1):29. doi: 10.1186/s13321-021-00508-0.
4
QSAR Modeling for Multi-Target Drug Discovery: Designing Simultaneous Inhibitors of Proteins in Diverse Pathogenic Parasites.用于多靶点药物发现的定量构效关系建模:设计针对多种致病寄生虫中蛋白质的同时抑制剂
Front Chem. 2021 Mar 10;9:634663. doi: 10.3389/fchem.2021.634663. eCollection 2021.
5
Mnk inhibitors: a patent review.Mnk 抑制剂:专利研究综述
Pharm Pat Anal. 2021 Jan;10(1):25-35. doi: 10.4155/ppa-2020-0028. Epub 2021 Jan 14.
6
One molecular fingerprint to rule them all: drugs, biomolecules, and the metabolome.一种分子指纹统御万物:药物、生物分子与代谢组。
J Cheminform. 2020 Jun 12;12(1):43. doi: 10.1186/s13321-020-00445-4.
7
QSAR without borders.无边界定量构效关系。
Chem Soc Rev. 2020 Jun 7;49(11):3525-3564. doi: 10.1039/d0cs00098a. Epub 2020 May 1.
8
Methods for Design of Kinase Inhibitors as Anticancer Drugs.激酶抑制剂作为抗癌药物的设计方法。
Front Chem. 2020 Jan 8;7:873. doi: 10.3389/fchem.2019.00873. eCollection 2019.
9
Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.针对 MAPK 相互作用激酶 1 和 2 的片段命中的逐步进化。
J Med Chem. 2020 Jan 23;63(2):621-637. doi: 10.1021/acs.jmedchem.9b01582. Epub 2020 Jan 7.
10
Multi-Target Chemometric Modelling, Fragment Analysis and Virtual Screening with ERK Inhibitors as Potential Anticancer Agents.多靶点化学计量学建模、片段分析和虚拟筛选,以 ERK 抑制剂作为潜在的抗癌药物。
Molecules. 2019 Oct 30;24(21):3909. doi: 10.3390/molecules24213909.